By John Vandermosten, CFANASDAQ:VVUSREAD THE FULL VVUS RESEARCH REPORT We are initiating coverage of VIVUS, Inc. (NASDAQ:VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic insufficiency (EPI) and erectile dysfunction (ED) solutions, Vivus maintains...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdatePhase 2b Trial for VK2809 to Initiate 2H19Viking Therapeutics, Inc. (NASDAQ:VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). A...
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ1 2019 Results: Record Revenue, EPS. Cash Flow Increasing. Infrastructure Investments Based on Demand…Semler Scientific (OTC:SMLR) reported financial results for their first quarter ending March 31, 2019. Revenue was about 2% better than our estimate, up nearly 52% from the...
By Lisa ThompsonNASDAQ:MOGOREAD THE FULL MOGO RESEARCH REPORT Mogo (NASDAQ:MOGO) is a rapidly growing Canadian fintech company with over 800K members that generates revenues from a series of innovative products to help consumers manage & control their financial health. These products include a digital spending account with a Platinum Prepaid Visa Card, ID Fraud protection...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateAdditional Data Presented for Exebacase Phase 2 TrialOn April 16, 2019, Contrafect Corp. (NASDAQ:CFRX) announced the presentation of new data from the Phase 2 clinical trial of exebacase (CF-301) for the treatment of Staphylococcus aureus bacteremia including endocarditis at the...
NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) will be releasing highly anticipated interim data from its Phase I clinical trial this quarter. The readout will be for CK-301, an anti-PD-L1 antibody, which is expected to include safety and efficacy data from approximately 40-50 patients with a variety of tumor types...
By Steven Ralston, CFAOTC:ALPEREAD THE FULL ALPE RESEARCH REPORT alpha-En Corp (OTC:ALPE) is a technology development company, primarily focusing on the development of a commercially viable process for the production of high-purity lithium metal and of a thin film lithium anode for use in the next generation of lithium high-energy...
By John Vandermosten, CFAOTC:GOVXREAD THE LATEST GOVX RESEARCH REPORT GeoVax Labs, Inc. (OTC:GOVX) held its special meeting of stockholders and shareholder vote on April 15, 2019. There was a 97.7% response rate for the issued and outstanding shares, representing 252.2 million equity units. The key matters under consideration...
By John Vandermosten, CFANASDAQ:PHIOREAD THE LATEST PHIO RESEARCH REPORT Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported fourth quarter and full year results and filed its Form 10-K on March 27, 2018. Key operational events in 2018 include data presentations on NK cells, collaborations with Karolinska Institutet and Iovance Biotherapeutics and positive...
By John Vandermosten, CFATSX:RVX Resverlogix Corp. (TSX:RVX) reported today that it has observed the targeted 250 events in its Phase III BETonMACE trial which began in November 2015. The drug under investigation, apabetalone, is being investigated in a trial with 2,425 participants and was fully enrolled in March 2018....